Cases & Deals

  • Home
  • Practices
  • Purdue enforces formulation and compound patents against Collegium Pharmaceutical's Xtampza® ER extended-release oxycodone capsules

Share

Purdue enforces formulation and compound patents against Collegium Pharmaceutical's Xtampza® ER extended-release oxycodone capsules

November 2021

Client(s) Purdue Pharma L.P.

Jones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against Collegium Pharmaceutical, Inc., relating to Collegium's submission of a Section 505(b)(2) application for its Xtampza® ER extended-release oxycodone capsules.

Purdue Pharma LP et al v. Collegium Pharmaceutical, Inc., No. 1-15-cv-13099 (D. Mass.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.